Both insulins will have 50 percent lower list prices compared to the branded versions and will be available by mid-April.
With these new options, more than 90 percent of people using a Humalog formulation will have access to a lower-priced version that may reduce their out-of-pocket costs.
These insulins are identical to branded versions and may be substituted at the pharmacy counter. Because most insurance plans provide affordable copays for chronic medicines that are much lower than the list price, people should ask their pharmacist whether these options reduce their out-of-pocket cost.
First lower-priced insulin, Insulin Lispro, became available in May 2019 at a 50 percent lower list price. All major U.S. wholesalers now distribute Lispro and it can be ordered by any pharmacy, usually in 1-2 days.
More than 95 percent of people using Humalog pay less than $100 for their monthly prescription at retail pharmacies because of their insurance coverage or one of Lilly’s affordability solutions.